60 related articles for article (PubMed ID: 17688945)
41. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.
Sosin AM; Burger AM; Siddiqi A; Abrams J; Mohammad RM; Al-Katib AM
J Hematol Oncol; 2012 Sep; 5():57. PubMed ID: 22989009
[TBL] [Abstract][Full Text] [Related]
42. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
[TBL] [Abstract][Full Text] [Related]
43. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Paquette RL; Nicoll J; Chalukya M; Gondek L; Jasek M; Sawyers CL; Shah NP; Maciejewski J
Leuk Res; 2010 Jun; 34(6):708-13. PubMed ID: 19804904
[TBL] [Abstract][Full Text] [Related]
44. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.
Kalla C; Scheuermann MO; Kube I; Schlotter M; Mertens D; Döhner H; Stilgenbauer S; Lichter P
Eur J Cancer; 2007 May; 43(8):1328-35. PubMed ID: 17449237
[TBL] [Abstract][Full Text] [Related]
45. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia.
Mansouri L; Gunnarsson R; Sutton LA; Ameur A; Hooper SD; Mayrhofer M; Juliusson G; Isaksson A; Gyllensten U; Rosenquist R
Am J Hematol; 2012 Jul; 87(7):737-40. PubMed ID: 22674506
[TBL] [Abstract][Full Text] [Related]
46. p53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia.
Bromidge T; Lowe C; Prentice A; Johnson S
Br J Haematol; 2000 Oct; 111(1):223-9. PubMed ID: 11091205
[TBL] [Abstract][Full Text] [Related]
47. Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia.
Véronèse L; Tournilhac O; Verrelle P; Davi F; Dighiero G; Chautard E; Veyrat-Masson R; Kwiatkowski F; Goumy C; Gouas L; Bay JO; Vago P; Tchirkov A
Leuk Res; 2009 Dec; 33(12):1623-6. PubMed ID: 19487028
[TBL] [Abstract][Full Text] [Related]
48. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
49. A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies.
Newcomb EW; el Rouby S; Thomas A
Mol Carcinog; 1995 Dec; 14(4):227-32. PubMed ID: 8519411
[TBL] [Abstract][Full Text] [Related]
50. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia.
Pekova S; Cmejla R; Smolej L; Kozak T; Spacek M; Prucha M
Leuk Res; 2008 Mar; 32(3):395-400. PubMed ID: 17688945
[TBL] [Abstract][Full Text] [Related]
51. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.
Plass C; Byrd JC; Raval A; Tanner SM; de la Chapelle A
Br J Haematol; 2007 Dec; 139(5):744-52. PubMed ID: 17961188
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
